Kyushu University Academic Staff Educational and Research Activities Database
Researcher information (To researchers) Need Help? How to update
Kentaro Inoue Last modified date:2024.04.24

Assistant Professor / Department of Surgery and Science
Department of Clinical Medicine
Faculty of Medical Sciences


Graduate School


Homepage
https://kyushu-u.elsevierpure.com/en/persons/kentaro-inoue
 Reseacher Profiling Tool Kyushu University Pure
Academic Degree
DOCTOR OF PHILOSOPHY (Medical Science)
Country of degree conferring institution (Overseas)
No
Field of Specialization
Vascular Surgery
Research
Academic Activities
Papers
1. Kentaro Inoue, Tadashi Furuyama, Shun Kurose, Shinichiro Yoshino, Ken Nakayama, Sho Yamashita, Koichi Morisaki, Masazumi Kume, Takuya Matsumoto, Masaki Mori , Platelets reflect the fate of type II endoleak after endovascular aneurysm repair., Journal of vascular surgery, 10.1016/j.jvs.2019.09.062, 72, 2, 541-548, 2020.08, OBJECTIVE: The management of type II endoleak (T2E) remains controversial because of the heterogeneous outcome. For blood-based screening to detect malignant T2E, we focused on platelets after endovascular aneurysm repair (EVAR) and compared them with the prognosis of T2Es. METHODS: From 2007 to 2015, there were 249 patients treated with EVAR for abdominal aortic aneurysm who were evaluated retrospectively. The mean follow-up period was 3.5 +/- 0.2 years. T2Es that had aneurysm sac enlargement or converted to type I or type III endoleak were defined as malignant; the other T2Es were considered benign. Cases without any complications, including T2E, were defined as completed. We compared the platelet count on postoperative days (PODs) 1 to 7 with preoperative baseline values among the three groups. Sequentially, we calculated the cutoff of the platelet ratio on POD 7 to the baseline value in relation to malignant T2E using receiver operating characteristic analysis, and the cutoff ratio was 113% (sensitivity, 79%; specificity, 58%). We then reclassified T2E patients into T2E-high platelet (T2E-HP; >/=113%) or T2E-low platelet (T2E-LP; .